Tempest Therapeutics (TPST) Income from Continuing Operations (2012 - 2026)
Tempest Therapeutics (TPST) posted Income from Continuing Operations of 4077000.0 for Q4 2025, up 71.67% sequentially from 14392000.0 in Q3 2025, and up 71.2% YoY from 2381460.61 in Q4 2024.
Tempest Therapeutics (TPST) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Tempest Therapeutics has reported Income from Continuing Operations for 14 years, with the latest figure at 4077000.0 in Q4 2025.
- Quarterly Income from Continuing Operations rose 71.2% year-over-year to 4077000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 40130000.0 (up 7.39% YoY) and the FY2025 annual result came in at 28785000.0, up 86.85% from the prior year.
- Income from Continuing Operations rose to 4077000.0 in Q4 2025 per TPST's latest filing, from 14392000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1699000.0 in Q4 2023 and troughed at 14392000.0 in Q3 2025.
- A 5-year average of 8453450.0 and a median of 8671500.0 in 2021 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2021 and 2024: Income from Continuing Operations soared 88.94% in 2021, then sank 733.14% in 2024.
- Over 5 years, Income from Continuing Operations stood at 3789000.0 in 2021, then sank by 147.19% to 9366000.0 in 2022, then jumped by 81.86% to 1699000.0 in 2023, then sank by 733.14% to 14155000.0 in 2024, then jumped by 71.2% to 4077000.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 4077000.0, 14392000.0, and 10564000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | -5.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.25 Mn |
| Dec 31, 2025 | -4.08 Mn |
| Sep 30, 2025 | -14.39 Mn |
| Jun 30, 2025 | -10.56 Mn |
| Mar 31, 2025 | -11.10 Mn |
| Dec 31, 2024 | -14.16 Mn |
| Sep 30, 2024 | -10.88 Mn |
| Jun 30, 2024 | -9.95 Mn |
| Mar 31, 2024 | -8.34 Mn |
| Dec 31, 2023 | -1.70 Mn |
| Sep 30, 2023 | -6.97 Mn |
| Jun 30, 2023 | -7.83 Mn |
| Mar 31, 2023 | -7.93 Mn |
| Dec 31, 2022 | -9.37 Mn |
| Sep 30, 2022 | -9.05 Mn |
| Jun 30, 2022 | -9.23 Mn |
| Mar 31, 2022 | -8.85 Mn |
| Dec 31, 2021 | -3.79 Mn |
| Sep 30, 2021 | -8.49 Mn |
| Jun 30, 2021 | -7.06 Mn |